Depletion of l-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes

European Journal of Haematology

Volumn 83, Issue 2, 2009, Pages 108-118

  Park, Chan H ^a   Kimler, Bruce F ^b   Yi, Seong Yoon ^a   Park, Se Hoon ^a   Kim, Kihyun ^a   Jung, Chul Won ^a   Kim, Sun Hee ^a   Lee, Eun Ryung ^a   Rha, Miyong ^a   Kim, Seonwoo ^a   Park, Mary H ^a   Lee, Sook J ^a   Park, Hye K ^a   Lee, Mark H ^c   Yoon, Sung Soo ^d   Min, Yoo Hong ^e   Kim, Bong Seog ^f   Kim, Jeong A ^g   Kim, Won Seog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c Konkuk University Hospital   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Seoul Veterans Hospital   (South Korea)

^g The Catholic University of Korea   (South Korea)

Author keywords

Cancer; clonogenic assay; vitamin C

Indexed keywords

ASCORBIC ACID; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; MITOXANTRONE; TOPOTECAN;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEPLETION; DIET THERAPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SCURVY; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ASCORBIC ACID; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 67650754251     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01252.x     Document Type: Article

References (47)

1. Park CH, Wiernik PH, Morrison FS, Amare M, VanSloten K, Maloney TR. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. Cancer Res 1983 43 : 2346 9.
2. Park CH, Amare M, Wiernik PH, Morrison FS, Dutcher JP, Maloney TR. In vitro drug sensitivity of leukemic colony-forming cells in acute nonlymphocytic leukemia: clinical correlation update with various drug exposure methods. In : Salmon SE, Trent JM, eds. Human Tumor Cloning. New York, NY : Grune and Stratton, 1984 : 619 26.
3. Park CH, Kimler BF. Cellular basis for growth promotion of human leukemic cells by l-ascorbic acid. J Nutr Growth Cancer 1986 3 : 131 4.
4. Park CH. Humoral regulation of human leukemic progenitor cell cycle: the case for turning off the cell cycle. J Lab Clin Med 1987 109 : 571 4.
5. Park CH, Kimler BF. Cyclic AMP modulation of leukemic cell growth in acute nonlymphocytic leukemia. J Nutr Growth Cancer 1987 4 : 141 6.
6. Park CH. Vitamin C in leukemia and preleukemia cell growth. In : Prasad K, Tryfiates GP, eds. Nutrition, Growth and Cancer. New York, NY : Alan R. Liss, 1987 : 321 30.
7. Park CH, Kimler BF, Bodensteiner D, Lynch SR, Hassanein RS. In vitro growth modulation by l-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes. Cancer Res 1992 52 : 4458 66.
8. Park CH, Kimler BF. Growth modulation of human leukemic, preleukemic and myeloma progenitor cells by l-ascorbic acid. Am J Clin Nutr 1991 54 : 1241S 6S.
9. Park CH, Amare M, Savin M, Hoogstraten B. Growth suppression of human leukemic cells in vitro by l-ascorbic acid. Cancer Res 1980 40 : 1062 5.
10. Witenberg B, Kalir HH, Raviv Z, Kletter Y, Kravtsov V, Fabian I. Inhibition by ascorbic acid of apoptosis induced by oxidative stress in HL-60 myeloid leukemia cells. Biochem Pharmacol 1999 57 : 823 32.
11. Park S, Han SS, Park CH, et al. l-ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. Int J Biochem Cell Biol 2004 36 : 2180 95.
12. Han S-S, Kim K, Hahm E-R, et al. l-ascorbic acid represses constitutive activation of NF-κB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 2004 93 : 257 70.
13. Park S, Park CH, Hahm E-R, et al. Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. Cell Signal 2005 17 : 111 9.
14. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 2005 102 : 13604 9.
15. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999 59 : 4555 8.
16. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implication for oral and intravenous use. Ann Intern Med 2004 140 : 533 7.
17. Migliozzi JA. Effect of ascorbic acid on tumor growth. Br J Cancer 1977 35 : 448 53.
18. Telang S, Clem AL, Eaton JW, Chesney J. Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia 2007 9 : 47 56. (Pubitemid 46206018)
19. Ohtani S, Iwamaru A, Deng W, et al. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res 2007 67 : 6293 303.
20. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 1976 73 : 3685 9.
21. Moertel CG, Fleming TR, Creagan ET, et al. High dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. N Engl J Med 1985 312 : 137 41.
22. Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005 24 : 269 76.
23. Padayatty SJ, Riordan HD, Hewitt SM, et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006 28 : 937 42.
24. ClinicalTrials.gov. Identifier NCT00441207: A phase I study of high-dose IV vitamin C treatment in patients with solid tumors.
25. ClinicalTrials.gov. Identifier NCT00284427: Safety of oral antioxidants and intravenous vitamin C during GYN cancer care.
26. ClinicalTrials.gov. Identifier NCT00626444: Phase II trial of high dose intravenous vitamin C in patients with refractory non-Hodgkin lymphoma.
27. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976 33 : 451 8.
28. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000 72 : 131 3.
29. Cammack J, Oke A, Adams RN. Simultaneous high-performance liquid chromatographic determination of ascorbic acid and dehydroascorbic acid in biological samples. J Chromatogr 1991 565 : 529 32.
30. Crandon JH, Lund CC, Dill DB. Experimental human scurvy. N Engl J Med 1940 223 : 353 69.
31. Peters RA. for the Accessory Food Factors Committee, Medical Research Council. Vitamin-C requirement of human adults. Experimental study of vitamin-C deprivation in man. Lancet 1948 1 : 853 8.
32. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008 19 : 1969 74.
33. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of resoponse criteria, treatment outcomes, reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003 21 : 4642 9.
34. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000 96 : 3671 4.
35. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biological and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004 103 : 3669 76.
36. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003 102 : 2763 7.
37. Fiedler W, Serve H, Döhner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005 105 : 986 93.
38. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005 105 : 54 60. (Pubitemid 40053063)
39. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989 10 : 1 10. (Pubitemid 19099520)
40. Goldberg SL, Madan RA, Rowley SD, Pecora AL, Hsu JW, Tantravahi R. Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy. Blood 2003 101 : 781. (Pubitemid 36077608)
41. th Karnofsky Memorial Lecture, Annual Meeting of the American Society of Clinical Oncology; 31 May 2008. 2008
42. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007 6 : 273 86.
43. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J 2008 27 : 7 19.
44. Li Y, Schellhorn HE. New developments and novel therapeutic perspectives for vitamin C. J Nutr 2007 137 : 2171 84.
45. Chang J, Voorhees P, Kolesar J, Ahuja H, Sanchez F, Rodriguez G, Kim K, Werndli J, Bailey H, Kahl B. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol 2009 27 : 11 6.
46. Bael TE, Peterson BL, Gollob JA. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 2008 18 : 147 51.
47. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008 68 : 8031 8.